Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/15/2018 02/16/2018 02/20/2018 02/21/2018 02/22/2018 Date
164.47(c) 164.04(c) 160.59(c) 159.31(c) 159.4 Last
3 403 883 2 689 078 2 468 594 2 688 037 2 763 960 Volume
-1.30% -0.26% -2.10% -0.80% +0.06% Change
More quotes
Financials ($)
Sales 2018 15 195 M
EBIT 2018 7 274 M
Net income 2018 -1 302 M
Debt 2018 22 990 M
Yield 2018 1,83%
Sales 2019 15 692 M
EBIT 2019 7 591 M
Net income 2019 -648 M
Debt 2019 20 053 M
Yield 2019 1,89%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 5,00x
EV / Sales2019 4,65x
Capitalization 52 984 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International.The US Specialized Therapeutics segment includes sales and expenses relating to branded... 
Sector
Pharmaceuticals
Calendar
02/27Ex-dividend day for
More about the company
Surperformance© ratings of Allergan plc
Trading Rating : Investor Rating :
More Ratings
Latest news on ALLERGAN PLC
02:01pALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
PR
02/20ALLERGAN : Presents Data at the 2018 American Academy of Dermatology Annual Meet..
AQ
02/17ALLERGAN : Presents Data at the 2018 American Academy of Dermatology (AAD) Annua..
PU
02/16ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/15ALLERGAN : Trademark Application for "REJUVACROSS" Filed by Allergan
AQ
02/15ALLERGAN : An Application for the Trademark "REJUVECROSS" Has Been Filed by Alle..
AQ
02/15ALLERGAN : Matthew M. Walsh Appointed Executive Vice President and Chief Financi..
AQ
02/14ALLERGAN : s Forest Labs pays 726m in dividend
AQ
02/13ALLERGAN : Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share..
AQ
02/09ALLERGAN (NYSE : AGN) announces a quarterly dividend of  $0.72
AQ
More news
Sector news : Pharmaceuticals - NEC
02:56pNOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
07:21aSeed firms scramble to stop a 'cancer' in Canada's cash crop
RE
02/21ASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
RE
02/21MERCK : to Invest Additional EUR40 Million in Asia
DJ
02/21Merck to buy virus-based cancer drug firm Viralytics for $394 million
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
10:44p$WPI ALERT: New Allergan plc SEC Filing From our Stock News Alerts App 
04:04p$AGN: Allergan announces that the FDA has accpeted for filing Medicines360's .. 
02:56pAllergan partner Medicines360 files U.S. application for extended duration of.. 
12:26pQuotidian Technical Highlights on Selected Generic Drugs Stocks -- Allergan, .. 
12:16pAmica Mutual Insurance Co. Sells 9,113 Shares of Allergan plc $AGN  
More tweets
Qtime:237
News from SeekingAlpha
03:32pTracking Wallace Weitz's Weitz Investment Management Portfolio - Q4 2017 Upda.. 
08:56aAllergan partner Medicines360 files U.S. application for extended duration of.. 
08:47aAnother Phase III Win For Neurocrine Biosciences 
05:18aiShares Mortgage Real Estate ETF - Methodology Makes All The Difference 
02/21Tracking David Tepper's Appaloosa Management Portfolio - Q4 2017 Update 
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 217 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Matthew M. Walsh Chief Financial Officer & Executive VP
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-1.83%52 984
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618